California [US], November 4 (ANI): Patients with and without diabetes can benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are drugs that, among other things, reduce blood sugar levels and improve heart and kidney function.

The effects of sotagliflozin, a dual SGLT1 and 2 inhibitor, in individuals with type 2 diabetes and chronic kidney disease were recently discovered through an exploratory analysis.

Also Read | Snake Venom Drug Abuse: Can You Get High on Snake Bite Venom? Know About Snake Venom Drug Addiction, Symptoms, Side Effects and Treatment.

The study will be discussed at the 2023 ASN Kidney Week.

Data from the phase 3 double-blind, placebo-controlled SCORED trial, which randomised 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors to receive sotagliflozin or placebo, were used in the analysis. Laboratory-derived kidney and cardiorenal composites were among the outcomes evaluated.

Also Read | Cardiovascular-Related Deaths Due to Extreme Heat Expected To Increase Between 2036 and 2065, Says Study.

Sotagliflozin decreased the risk of the composite of persistent >=50 per cent drop in estimated glomerular filtration rate, estimated glomerular filtration rate

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)